Recent Report on Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016
Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Diffuse Large B-Cell Lymphoma (Oncology) pipeline landscape.
Diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma, is a cancer of B-cells. The lymphoma may metastasize to other organs such as the liver, lungs or the bones. The signs and symptoms of diffuse large B-cell lymphoma may include painless swelling in the neck, armpit or groin caused by enlarged lymph nodes, loss of appetite, tiredness, night sweats, unexplained high temperatures, and weight loss. The possible treatments for diffuse large B-cell lymphoma include radiation, chemotherapy, steroid therapy in combination with chemotherapy, high-dose chemotherapy with stem cell support and monoclonal antibody therapy.
Diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma, is a cancer of B-cells. The lymphoma may metastasize to other organs such as the liver, lungs or the bones. The signs and symptoms of diffuse large B-cell lymphoma may include painless swelling in the neck, armpit or groin caused by enlarged lymph nodes, loss of appetite, tiredness, night sweats, unexplained high temperatures, and weight loss. The possible treatments for diffuse large B-cell lymphoma include radiation, chemotherapy, steroid therapy in combination with chemotherapy, high-dose chemotherapy with stem cell support and monoclonal antibody therapy.
To access full report with TOC, please visit Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2016
Report Highlights
This report provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 57, 38, 30 and 5 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 2, 1 and 1 molecules, respectively for Diffuse Large B-Cell Lymphoma.
Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide reviews key companies involved in Diffuse Large B-Cell Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diffuse Large B-Cell Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
3SBio Inc. AbbVie Inc Acetylon Pharmaceuticals, Inc. Affimed GmbH Amgen Inc. Arrien Pharmaceuticals, LLC Arvinas, Inc. Asana BioSciences, LLC AstraZeneca Plc Aurigene Discovery Technologies Limited Bayer AG BeiGene, Ltd. Biocon Limited BioNTech AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corporation Cell Medica Limited Cell>Point, L.L.C. Cellular Biomedicine Group, Inc. Clevexel Pharma SA Constellation Pharmaceuticals, Inc. CSPC Pharmaceutical Group Limited CTI BioPharma Corp. Curis, Inc. Cyclacel Pharmaceuticals, Inc. eFFECTOR Therapeutics, Inc. Eisai Co., Ltd. EpiZyme, Inc. Erytech Pharma SA Evotec AG F. Hoffmann-La Roche Ltd. Genentech, Inc. Genosco Gilead Sciences, Inc. GlaxoSmithKline Plc H3 Biomedicine Inc. Hutchison MediPharma Limited ImmunoGen, Inc. Immunomedics, Inc. Immunovaccine, Inc. Incyte Corporation Inflection Biosciences Limited Innovent Biologics, Inc. Johnson & Johnson Juno Therapeutics Inc. Karyopharm Therapeutics, Inc. Kite Pharma Inc Mabion SA mAbxience S.A. MedImmune LLC Medivation, Inc. Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals Inc Mirati Therapeutics Inc. Molplex Ltd. MorphoSys AG Neumedicines Inc. Nimbus Therapeutics, LLC Nordic Nanovector ASA Novartis AG Ono Pharmaceutical Co., Ltd. Pfizer Inc. Philogen S.p.A. Portola Pharmaceuticals, Inc. RedHill Biopharma Ltd. Respiratorius AB Rhizen Pharmaceuticals S.A. Sandoz International GmbH Seattle Genetics, Inc. Selvita S.A. Shanghai Henlius Biotech Co., Ltd. Sigma-Tau S.p.A. Taiho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited TG Therapeutics, Inc. TRACON Pharmaceuticals Inc
Report Highlights
This report provides comprehensive information on the therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology), complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Diffuse Large B-Cell Lymphoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 10, 57, 38, 30 and 5 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 5, 2, 1 and 1 molecules, respectively for Diffuse Large B-Cell Lymphoma.
Diffuse Large B-Cell Lymphoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diffuse Large B-Cell Lymphoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide reviews key companies involved in Diffuse Large B-Cell Lymphoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Diffuse Large B-Cell Lymphoma (Oncology) therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Diffuse Large B-Cell Lymphoma (Oncology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Diffuse Large B-Cell Lymphoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Diffuse Large B-Cell Lymphoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
3SBio Inc. AbbVie Inc Acetylon Pharmaceuticals, Inc. Affimed GmbH Amgen Inc. Arrien Pharmaceuticals, LLC Arvinas, Inc. Asana BioSciences, LLC AstraZeneca Plc Aurigene Discovery Technologies Limited Bayer AG BeiGene, Ltd. Biocon Limited BioNTech AG Boehringer Ingelheim GmbH Bristol-Myers Squibb Company Celgene Corporation Cell Medica Limited Cell>Point, L.L.C. Cellular Biomedicine Group, Inc. Clevexel Pharma SA Constellation Pharmaceuticals, Inc. CSPC Pharmaceutical Group Limited CTI BioPharma Corp. Curis, Inc. Cyclacel Pharmaceuticals, Inc. eFFECTOR Therapeutics, Inc. Eisai Co., Ltd. EpiZyme, Inc. Erytech Pharma SA Evotec AG F. Hoffmann-La Roche Ltd. Genentech, Inc. Genosco Gilead Sciences, Inc. GlaxoSmithKline Plc H3 Biomedicine Inc. Hutchison MediPharma Limited ImmunoGen, Inc. Immunomedics, Inc. Immunovaccine, Inc. Incyte Corporation Inflection Biosciences Limited Innovent Biologics, Inc. Johnson & Johnson Juno Therapeutics Inc. Karyopharm Therapeutics, Inc. Kite Pharma Inc Mabion SA mAbxience S.A. MedImmune LLC Medivation, Inc. Merck & Co., Inc. Merck KGaA Millennium Pharmaceuticals Inc Mirati Therapeutics Inc. Molplex Ltd. MorphoSys AG Neumedicines Inc. Nimbus Therapeutics, LLC Nordic Nanovector ASA Novartis AG Ono Pharmaceutical Co., Ltd. Pfizer Inc. Philogen S.p.A. Portola Pharmaceuticals, Inc. RedHill Biopharma Ltd. Respiratorius AB Rhizen Pharmaceuticals S.A. Sandoz International GmbH Seattle Genetics, Inc. Selvita S.A. Shanghai Henlius Biotech Co., Ltd. Sigma-Tau S.p.A. Taiho Pharmaceutical Co., Ltd. Takeda Pharmaceutical Company Limited TG Therapeutics, Inc. TRACON Pharmaceuticals Inc
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
​Reportstack Market Research
###
posted by Reportstack @ 07:30
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home